An open-label study to define the safety tolerability and clinical activity of deutetrabenazine (Austedo) in adult study subjects with dystonia
Recruiting
18-99 years
All
Phase
3
15 participants needed
1 Location
Brief description of study
The purpose of this research study is to explore the safety and tolerability of the daily oral administration of
deutetrabenazine, whose trade name is Austedo, in adults with dystonia.
Detailed description of study
The study is being conducted at the Parkinson’s Disease and Movement Disorders Center of the University of
Pennsylvania. Approximately 15 men and women over the age of 18 who have been diagnosed with dystonia will
take part in this study. Participants will be patients whose dystonia is being managed at the University of
Pennsylvania or are referred to this center for the purpose of participating in this trial.
Your participation in the study will last for up to 13 weeks, with the length of time depending on how long it takes
to determine the appropriate dose of Austedo for you.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: dystonia,neuro
-
Age: Between 18 Years - 99 Years
-
Gender: All
Updated on
01 Aug 2024.
Study ID: 834104
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
